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Abstract
Purpose
Various profibrotic and proinflammatory cytokines have been found upregulated in uncom-
plicated primary retinal detachment (pRD), but without providing a uniform picture. Here, we
compare the cyto- and chemokine profiles in pRD with and without proliferative vitreoretino-
pathy (PVR) in an attempt to unravel relevant differences not in single cytokines, but in the
cytokine profiles at diagnosis.
Methods
Undiluted vitreous fluid (VF) was obtained at the beginning of surgery from 174 eyes with pRD
without relevant PVR (maximally grade B; group 1; n = 81) and with moderate or advanced
PVR requiring a gas tamponade (group 2; n = 49) or silicon oil filling (group 3; n = 44). VF of
eyes undergoing macular hole (MH) surgery served as controls (group 4; n = 26). Forty-three
cytokines were quantified in parallel using a multiplex cytokine analysis system (Bioplex). For
all comparisons we applied Holm’s correction to control for multiple comparisons.
Results
44.9% of group 2 eyes presented grade C1 and 55.1% C2-C3, whereas 86.4% of group 3
eyes exhibited a PVR grade of C2-D.
CCL19 was the only cytokine that displayed higher concentrations in the vitreous of eyes
with PVR C1 compared to lower PVR grades. Eyes with PVR C2-D showed higher levels of
CCL27, CXCL6, IL4, IL16, CXCL10, CCL8, CCL22, MIG/CXCL9, CCL15, CCL19, CCL 23
and CXCL12 compared to controls. Interestingly, no difference of cytokine levels was
detected between C1 and C2-D PVR.
Conclusions
CCL19 may represent a potential biomarker for early PVR progression that holds promise
for future diagnostic and therapeutic applications.
PLOS ONE | https://doi.org/10.1371/journal.pone.0214674 April 3, 2019 1 / 16
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Zandi S, Pfister IB, Traine PG, Tappeiner
C, Despont A, Rieben R, et al. (2019) Biomarkers
for PVR in rhegmatogenous retinal detachment.
PLoS ONE 14(4): e0214674. https://doi.org/
10.1371/journal.pone.0214674
Editor: Demetrios G. Vavvas, Massachusetts Eye &
Ear Infirmary, Harvard Medical School, UNITED
STATES
Received: November 28, 2018
Accepted: March 18, 2019
Published: April 3, 2019
Copyright: © 2019 Zandi et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: Independent unconditional funding was
received from the research funds of the Lindenhof
foundation for the project covering 30% of the
laboratory kits, but these were not personal
donations. The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript. There was no
additional external funding received for this study.
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
55
65
 
| 
do
wn
lo
ad
ed
: 
4.
12
.2
01
9
Introduction
Cell-signaling mediators, such as cytokines and chemokines are involved in the regulation of
inflammatory processes, wound healing and scar formation [1]. In eyes with retinal detach-
ment, elevated levels of a variety of cytokines and growth factors in the vitreous have been
reported [2–7].
Retinal detachment (RD) induces cell migration and proliferation as well as the production
of extracellular matrix proteins, which in turn lead to the development and contraction of
vitreal and periretinal membranes, both hallmarks of proliferative vitreoretinopathy (PVR)
[8,9,10]. PVR occurs in up to 10% of rhegmatogenous retinal detachment cases and is the
major cause of poor functional outcomes after primarily successful RD surgery [11,12].
Depending on the duration and extent of RD, the accumulation of fibroblasts, collagen, and
extracellular matrix components may co-occur with the formation of membranes on the vitre-
ous and the interfaces of the entire retina, including the still attached parts. Previous studies
found associations between PVR and significantly increased concentrations of certain pro-
inflammatory cytokines and growth factors in the vitreous [13–19]. The majority of which did
not exhibit any differences in their clinical relevance, except for IL-1, IL-6, IL-8, IL-10, TNF-
alpha, IL1-beta, IFN gamma, ICAM-1, PDGF, MIF (macrophage inhibitory factor) and the
chemokine ligands CCL2, CCL11, CCL17, CCL18, CCL19, CCL22, CXCL8, CXCL9 and
CXCL10 [17,18,20].
The aim of this study was to not only focus on single cytokines in the vitreous fluid (VF)
when comparing between cases with and without relevant PVR, but to provide a much broader
comparison of profiles of pro-inflammatory and pro-fibrotic cytokines in the vitreous fluid
(VF) which should facilitate an improved differentiation of their relative importance with
respect to the pathophysiological process of PVR.
Patients and methods
Patients
The investigation was designed as a prospective study involving consecutive patients undergo-
ing pars plana vitrectomy for the treatment of primary retinal detachment with and without
PVR and subsequent gas or silicon oil filling. All surgeries had been performed by the same
surgeon at the Berner Augenklinik am Lindenhofspital, Bern, Switzerland. Patients with sys-
temic or ocular comorbidities that may potentially influence ocular cytokine levels were
excluded, i.e. patients with diabetes mellitus, known rheumatic and autoimmune diseases, sys-
temic treatments involving corticosteroids or immunomodulatory drugs, vitreous hemorrhag-
ing, uveitis, glaucoma, or any concomitant retinal pathology, or who had undergone
intraocular surgery or treatment within six months of the RD diagnosis. If both eyes were
affected, only the first operated eye was included. The exclusion criteria apply also to the con-
trol group.
The study was approved by the Ethics committee of the University of Bern (KEK no. 152/
08), and is fully compliant with the tenets of the Declaration of Helsinki. Each participant pro-
vided their informed written consent to the use of their biological materials and clinical data.
PVR grading and patient grouping
Following recommendations from the “Retina Society Terminology Committee (1983)” [21],
we classified patients based on PVR severity into four stages: A (minimal), B, C, and D (mas-
sive). For the purpose of this study, we considered the risk of developing postoperative PVR to
be similar in pRD patients without PVR and pRD patients with low PVR severity (grades A or
Cytokine profiles and PVR development
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B) (denoted collectively as group 1, n = 81). On the basis of this classification system, PVR
grade C was further subcategorized into C1 –C3, with the numerals 1–3 referring to the num-
ber of quadrants with visible PVR membrane formation. If all 4 quadrants were affected, the
severity was defined as grade D. Since accurate grading in advanced PVR may be difficult,
wide field images (Optos TX200, Optos Inc, Dunfermline, Scotland) were obtained from all
eyes prior to surgery. To examine postoperative PVR risk, patients with advanced PVR were
grouped according to the intraoperative decision regarding the type of tamponade (Fig 1): eyes
receiving an SF6 gas tamponade were categorized as group 2 (n = 49, those in need of a silicone
oil tamponade are group 3 (n = 44), while those undergoing macular hole (MH) surgery with
SF6 gas tamponade served as control (group 4; n = 26).
Handling of vitreous fluid samples
Approximately 500 microliters of undiluted VF were collected at the beginning of pars plana
vitrectomy. After harvesting, the VF initially stored at -20˚C and moved to -80˚C after
Fig 1. Schematic diagram of groups and PVR grades. Group 1 eyes showed a maximal PVR grade A or B (no relevant vascular wrinkling),
whereas 44.9% of group 2 presented a PVR grade C1 and in 55.1% grades C2 or C3. However, 86.4% of eyes in group 3 exhibited a PVR grade of
C2-D and required silicone oil tamponade. Therefore, we labeled these groups as “without relevant PVR” (group 1), moderate (group 2) and
advanced PVR (group 3).
https://doi.org/10.1371/journal.pone.0214674.g001
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maximally 2 months where it remained until the final analysis which was performed on all
samples simultaneously.
Cytokine analyses
The samples were analyzed using a multiplex system (Bio-Plex 100 array reader with Bio-Plex
Manager software version 6.1; Bio-Rad, Hercules, CA, USA). With this highly sensitive tech-
nique, multiple analytes can be detected in parallel using a single small volume sample. We
quantified the concentrations of 43 cytokines in each vitreous sample (Tables 1–6). All analytic
procedures were performed following the manufacturer’s instructions. In short, magnetic
microspheres, tagged with a fluorescent label were coupled to specific capture antibodies and
mixed with samples containing unknown cytokine quantities before introducing biotinylated
detection antibodies and Streptavidin R-Phycoerythrin. The mixture was then analyzed by
flow cytometry. The instrument’s two lasers identify the microsphere type and quantify the
amount of bound antigen. On each test plate we ran a duplicate concentration standard in par-
allel for each cytokine. The measurements were performed in a blinded manner by a labora-
tory technician who was experienced in the execution of this technique.
Statistical analyses
By performing a Shapiro-Wilk test we found that our data were not normally distributed. As a
result, we employed a non-parametric Mann-Whitney U test for the inter-group and intra-group
comparisons. A p-value of<0.05 was considered to be significant. Since multiple comparisons
increase the risk of introducing a Type-I error, we applied the sequentially rejective Bonferroni
correction (Holm’s correction) to control for this type of error without introducing additional
Type II errors [22,23]. This means that the p-value must be divided by the number of tests run in
parallel, resulting in an adjusted level of statistical significance of p = 0.05/43 = 0.00116. All statis-
tical analyses were performed using R (package FSA, software version 3.4.0).
Results
Patients
The eyes of 174 consecutive patients admitted to our clinic for primary retinal detachment met
the inclusion criteria (group 1 n = 81; group 2 n = 49; group 3 n = 44). Thereof, 92 eyes were
phakic and 82 eyes were pseudophakic (group1: n = 40, group 2: n = 17, group 3: n = 25). In
the control group (group 4), 26 patients with macular hole underwent pars plana vitrectomy,
all of which were phakic before surgery. Since we recently showed that the lens status does not
significantly influence the cytokine profiles in the VF phakic and pseudophakic eyes in each
group were pooled [24].
The mean age in group 4 was higher than in groups 1 and 2 while similar to group 3 (group
4 (control): 67.5 ± 8.2 years; group 1: 61.6 ± 14.3 years; group 2: 61.9± 9.6; group 3: 68.5±
14.1). While the control group (group 4) and group 2 were predominantly female (group 4:
19.2% males, 80.8% females, group 2: 38.8% males, 60.2% females) group 1 and 3 contained
male majorities (group 1: 65.4% males; group 3: 59.1% males). However there were no signifi-
cant differences in gender between the RD groups.
Comparison of cytokine profiles in macular hole and pRD
Compared to the control group, pRD patients both with or without PVR displayed signifi-
cantly higher levels of all chemo- and cytokines in the VF, except for TGF beta-1 and -2, even
after correction for multiple comparisons (Fig 2).
Cytokine profiles and PVR development
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Table 1. Mean concentrations (pg/ml) and standard deviations (SD) of cytokines in the vitreous of eyes with primary retinal detachment without PVR (pRD) and
in eyes with primary retinal detachment with moderate PVR treated with SF6 gas tamponade.
Cytokine pRD moderate PVR Mann-Whitney U test
Mean (pg/ml) SD Mean (pg/ml) SD
CCL21 2381.8 5022.1 1994.3 2675.1 p = 0.333
CXCL13 1.9 2.8 2.3 2.7 p = 0.01795
CCL27 10.6 41.0 11.5 24.2 p = 0.08551
CXCL5 164.7 195.1 189.8 184.3 p = 0.2683
CCL11 13.1 16.1 16.4 17.2 p = 0.04332
CCL24 21.4 22.2 22.1 14.0 p = 0.1448
CCL26 9.9 14.5 12.1 15.5 p = 0.03833
CX3CL1 67.7 70.9 88.9 91.0 p = 0.05434
CXCL6 2.3 3.8 3.5 4.8 p = 0.08683
GM-CSF 45.9 18.0 49.5 21.2 p = 0.3153
CXCL1 66.4 64.0 80.3 62.0 p = 0.03006
CXCL2 22.5 51.1 46.6 96.9 p = 0.01459
CCL1 35.5 59.3 49.0 68.1 p = 0.02713
IFN-γ 8.7 11.9 11.8 14.3 p = 0.1089
IL-1β 1.5 2.2 2.3 3.1 p = 0.02623
IL-2 1.5 1.8 1.8 1.3 p = 0.02031
IL-4 3.0 4.8 4.8 5.7 p = 0.03141
IL-6 136.0 349.1 418.3 1393.3 p = 0.0312
IL-8/CXCL8 36.5 51.2 46.1 51.9 p = 0.04618
IL-10 7.2 5.4 8.6 4.6 p = 0.0295
IL-16 57.6 45.1 92.3 110.0 p = 0.01556
CXCL10 350.3 1529.3 303.0 628.0 p = 0.07788
CXCL11 5.0 8.1 5.7 7.2 p = 0.1627
CCL2 1602.8 1597.1 1892.5 1415.4 p = 0.04438
CCL8 12.4 30.6 13.2 18.7 p = 0.03119
CCL7 21.8 26.0 29.3 32.4 p = 0.08307
CCL13 2.3 2.4 3.1 3.3 p = 0.01818
CCL22 14.0 17.3 15.1 11.6 p = 0.2365
MIF 101278.2 99480.3 113452.4 105774.0 p = 0.5058
MIG/CXCL9 304.1 2254.6 138.7 666.4 p = 0.09597
CCL3 3.1 2.7 4.0 3.2 p = 0.02018
CCL15 712.1 600.2 930.3 1049.4 p = 0.3806
CCL20 10.9 14.9 17.4 25.6 p = 0.0232
CCL19 38.1 62.8 47.4 48.9 p = 0.002001
CCL23 17.4 19.9 21.6 24.6 p = 0.1465
CXCL16 812.5 313.6 911.5 312.8 p = 0.0816
CXCL12 169.6 233.9 194.8 137.4 p = 0.003913
CCL17 6.4 19.2 8.4 15.1 p = 0.0775
CCL25 384.9 498.9 464.4 568.1 p = 0.08286
TNF-α 13.3 17.8 15.9 13.8 p = 0.04564
TGF-β1 100.1 215.5 34.5 74.2 p = 0.08435
TGF-β2 1243.6 823.9 871.0 673.7 p = 0.01038
TGF-β3 12.3 26.4 6.1 12.6 p = 0.2018
https://doi.org/10.1371/journal.pone.0214674.t001
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Table 2. Mean concentrations (pg/ml) and standard deviations (SD) of cytokines in the vitreous of eyes with primary retinal detachment without PVR (pRD) and
in eyes with primary retinal detachment with advanced PVR requiring silicone oil tamponade.
Cytokine pRD advanced PVR Mann-Whitney U test
Mean (pg/ml) SD Mean (pg/ml) SD
CCL21 2381.8 5022.1 4226.2 7403.1 p = 0.003323
CXCL13 1.9 2.8 4.1 8.0 p = 0.001729
CCL27 10.6 41.0 37.3 102.3 p = 1.27E-06
CXCL5 164.7 195.1 178.7 195.4 p = 0.7854
CCL11 13.1 16.1 20.8 22.2 p = 0.007636
CCL24 21.4 22.2 37.1 45.8 p = 0.00504
CCL26 9.9 14.5 17.3 19.2 p = 0.001253
CX3CL1 67.7 70.9 98.2 92.3 p = 0.009529
CXCL6 2.3 3.8 6.9 8.5 p = 0.0002024
GM-CSF 45.9 18.0 52.8 19.2 p = 0.04683
CXCL1 66.4 64.0 83.7 59.9 p = 0.01489
CXCL2 22.5 51.1 71.1 112.7 p = 0.004821
CCL1 35.5 59.3 65.6 97.6 p = 0.02381
IFN-γ 8.7 11.9 17.2 18.2 p = 0.00204
IL-1β 1.5 2.2 2.3 3.5 p = 0.08084
IL-2 1.5 1.8 2.0 1.5 p = 0.01801
IL-4 3.0 4.8 6.5 6.6 p = 0.0002875
IL-6 136.0 349.1 1348.3 6939.1 p = 0.007979
IL-8/CXCL8 36.5 51.2 55.2 59.7 p = 0.007763
IL-10 7.2 5.4 10.0 6.1 p = 0.006387
IL-16 57.6 45.1 119.4 113.4 p = 0.0002374
CXCL10 350.3 1529.3 418.4 590.2 p = 3.39E-05
CXCL11 5.0 8.1 7.9 10.0 p = 0.03648
CCL2 1602.8 1597.1 1815.8 1941.9 p = 0.7604
CCL8 12.4 30.6 19.6 24.8 p = 0.0003082
CCL7 21.8 26.0 35.9 35.3 p = 0.01288
CCL13 2.3 2.4 3.9 3.8 p = 0.01031
CCL22 14.0 17.3 27.8 25.4 p = 0.0001539
MIF 101278.2 99480.3 138533.6 128551.1 p = 0.07621
MIG/CXCL9 304.1 2254.6 470.3 1452.7 p = 1.05E-05
CCL3 3.1 2.7 4.6 4.3 p = 0.007524
CCL15 712.1 600.2 1901.6 2228.4 p = 0.0001252
CCL20 10.9 14.9 20.3 35.9 p = 0.00208
CCL19 38.1 62.8 93.7 143.2 p = 4.26E-05
CCL23 17.4 19.9 37.9 44.1 p = 1.27E-05
CXCL16 812.5 313.6 996.9 356.6 p = 0.003985
CXCL12 169.6 233.9 330.4 335.7 p = 2.07E-05
CCL17 6.4 19.2 14.0 26.8 p = 0.006175
CCL25 384.9 498.9 613.3 628.8 p = 0.005957
TNF-α 13.3 17.8 19.1 15.7 p = 0.005545
TGF-β1 100.1 215.5 118.6 214.8 p = 0.5693
TGF-β2 1243.6 823.9 1221.0 1213.8 p = 0.2869
TGF-β3 12.3 26.4 15.0 24.7 p = 0.7028
https://doi.org/10.1371/journal.pone.0214674.t002
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Table 3. Mean concentrations (pg/ml) and standard deviations (SD) of cytokines in the vitreous of eyes with primary retinal detachment with moderate PVR
treated with SF6 gas tamponade and in eyes with primary retinal detachment with advanced PVR requiring silicone oil tamponade.
Cytokine moderate PVR advanced PVR Mann-Whitney U test
Mean (pg/ml) SD Mean (pg/ml) SD
CCL21 1994.3 2675.1 4226.2 7403.1 p = 0.07548
CXCL13 2.3 2.7 4.1 8.0 p = 0.1684
CCL27 11.5 24.2 37.3 102.3 p = 0.003019
CXCL5 189.8 184.3 178.7 195.4 p = 0.5609
CCL11 16.4 17.2 20.8 22.2 p = 0.453
CCL24 22.1 14.0 37.1 45.8 p = 0.166
CCL26 12.1 15.5 17.3 19.2 p = 0.2041
CX3CL1 88.9 91.0 98.2 92.3 p = 0.4059
CXCL6 3.5 4.8 6.9 8.5 p = 0.03418
GM-CSF 49.5 21.2 52.8 19.2 p = 0.5081
CXCL1 80.3 62.0 83.7 59.9 p = 0.6035
CXCL2 46.6 96.9 71.1 112.7 p = 0.6324
CCL1 49.0 68.1 65.6 97.6 p = 0.8024
IFN-γ 11.8 14.3 17.2 18.2 p = 0.1102
IL-1β 2.3 3.1 2.3 3.5 p = 0.7817
IL-2 1.8 1.3 2.0 1.5 p = 0.7002
IL-4 4.8 5.7 6.5 6.6 p = 0.1649
IL-6 418.3 1393.3 1348.3 6939.1 p = 0.4236
IL-8/CXCL8 46.1 51.9 55.2 59.7 p = 0.4886
IL-10 8.6 4.6 10.0 6.1 p = 0.3951
IL-16 92.3 110.0 119.4 113.4 p = 0.1934
CXCL10 303.0 628.0 418.4 590.2 p = 0.01602
CXCL11 5.7 7.2 7.9 10.0 p = 0.4862
CCL2 1892.5 1415.4 1815.8 1941.9 p = 0.2015
CCL8 13.2 18.7 19.6 24.8 p = 0.1095
CCL7 29.3 32.4 35.9 35.3 p = 0.3634
CCL13 3.1 3.3 3.9 3.8 p = 0.4393
CCL22 15.1 11.6 27.8 25.4 p = 0.008345
MIF 113452.4 105774.0 138533.6 128551.1 p = 0.2813
MIG/CXCL9 138.7 666.4 470.3 1452.7 p = 0.002084
CCL3 4.0 3.2 4.6 4.3 p = 0.7033
CCL15 930.3 1049.4 1901.6 2228.4 p = 0.007758
CCL20 17.4 25.6 20.3 35.9 p = 0.3227
CCL19 47.4 48.9 93.7 143.2 p = 0.2001
CCL23 21.6 24.6 37.9 44.1 p = 0.0008617
CXCL16 911.5 312.8 996.9 356.6 p = 0.1895
CXCL12 194.8 137.4 330.4 335.7 p = 0.05835
CCL17 8.4 15.1 14.0 26.8 p = 0.3305
CCL25 464.4 568.1 613.3 628.8 p = 0.2154
TNF-α 15.9 13.8 19.1 15.7 p = 0.338
TGF-β1 34.5 74.2 118.6 214.8 p = 0.0453
TGF-β2 871.0 673.7 1221.0 1213.8 p = 0.1988
TGF-β3 1994.3 2675.1 15.0 24.7 p = 0.1831
https://doi.org/10.1371/journal.pone.0214674.t003
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Table 4. Mean concentrations (pg/ml) and standard deviations (SD) of cytokines in the vitreous of eyes with primary retinal detachment with PVR grade B or less
and in eyes with PVR C1.
Cytokine PVR grade B or less PVR grade C1 Mann-Whitney U test
Mean (pg/ml) SD Mean (pg/ml) SD
CCL21 2381.8 5022.1 2617.5 3303.7 p = 0.141
CXCL13 1.9 2.8 2.2 2.2 p = 0.01794
CCL27 10.6 41.0 11.0 21.0 p = 0.1178
CXCL5 164.7 195.1 211.5 196.1 p = 0.1571
CCL11 13.1 16.1 20.1 20.0 p = 0.02337
CCL24 21.4 22.2 24.3 16.1 p = 0.1088
CCL26 9.9 14.5 15.5 19.3 p = 0.02906
CX3CL1 67.7 70.9 95.3 93.8 p = 0.05406
CXCL6 2.3 3.8 3.7 5.7 p = 0.1644
GM-CSF 45.9 18.0 51.1 20.6 p = 0.2547
CXCL1 66.4 64.0 84.9 63.9 p = 0.02091
CXCL2 22.5 51.1 52.9 119.0 p = 0.09327
CCL1 35.5 59.3 60.2 79.5 p = 0.02523
IFN-γ 8.7 11.9 12.6 15.2 p = 0.1052
IL-1β 1.5 2.2 1.8 1.8 p = 0.2038
IL-2 1.5 1.8 1.8 1.3 p = 0.05152
IL-4 3.0 4.8 5.1 6.2 p = 0.0411
IL-6 136.0 349.1 572.6 1834.9 p = 0.1652
IL-8/CXCL8 36.5 51.2 43.5 43.5 p = 0.09129
IL-10 7.2 5.4 9.4 4.6 p = 0.01694
IL-16 57.6 45.1 73.6 45.4 p = 0.07492
CXCL10 350.3 1529.3 387.8 803.8 p = 0.1709
CXCL11 5.0 8.1 7.1 8.6 p = 0.07255
CCL2 1602.8 1597.1 1951.5 1681.5 p = 0.0596
CCL8 12.4 30.6 14.9 23.1 p = 0.06931
CCL7 21.8 26.0 34.0 39.3 p = 0.1071
CCL13 2.3 2.4 3.6 3.8 p = 0.01105
CCL22 14.0 17.3 18.2 21.1 p = 0.3609
MIF 101278.2 99480.3 124323.2 117135.7 p = 0.4085
MIG/CXCL9 304.1 2254.6 222.7 895.7 p = 0.07377
CCL3 3.1 2.7 4.5 4.0 p = 0.03388
CCL15 712.1 600.2 1166.5 1704.2 p = 0.4289
CCL20 10.9 14.9 15.2 17.0 p = 0.05405
CCL19 38.1 62.8 55.8 55.5 p = 0.0009894
CCL23 17.4 19.9 22.9 27.8 p = 0.1199
CXCL16 812.5 313.6 994.4 339.3 p = 0.02015
CXCL12 169.6 233.9 211.9 156.9 p = 0.006792
CCL17 6.4 19.2 10.4 18.5 p = 0.06664
CCL25 384.9 498.9 571.1 684.8 p = 0.03157
TNF-α 13.3 17.8 18.6 16.2 p = 0.01663
TGF-β1 100.1 215.5 41.8 134.9 p = 0.06634
TGF-β2 1243.6 823.9 899.5 677.8 p = 0.06155
TGF-β3 12.3 26.4 6.2 16.1 p = 0.08247
https://doi.org/10.1371/journal.pone.0214674.t004
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Table 5. Mean concentrations (pg/ml) and standard deviations (SD) of cytokines in the vitreous of eyes with primary retinal detachment with PVR grade B or less
and in eyes with primary retinal detachment and PVR C2-D.
Cytokine PVR grade B or less PVR grade C2 or higher Mann-Whitney U test
Mean (pg/ml) SD Mean (pg/ml) SD
CCL21 2381.8 5022.1 3268.7 6271.7 p = 0.02321
CXCL13 1.9 2.8 3.6 6.9 p = 0.001814
CCL27 10.6 41.0 29.4 86.2 p = 1.75E-05
CXCL5 164.7 195.1 174.5 187.2 p = 0.7461
CCL11 13.1 16.1 18.0 19.9 p = 0.01595
CCL24 21.4 22.2 31.6 38.8 p = 0.009679
CCL26 9.9 14.5 14.4 16.8 p = 0.002285
CX3CL1 67.7 70.9 93.3 91.4 p = 0.0134
CXCL6 2.3 3.8 5.7 7.4 p = 0.0004163
GM-CSF 45.9 18.0 51.7 19.5 p = 0.06252
CXCL1 66.4 64.0 81.1 60.2 p = 0.01964
CXCL2 22.5 51.1 57.3 96.8 p = 0.002432
CCL1 35.5 59.3 56.0 85.9 p = 0.02527
IFN-γ 8.7 11.9 15.4 17.0 p = 0.004325
IL-1β 1.5 2.2 2.5 3.7 p = 0.01877
IL-2 1.5 1.8 1.9 1.5 p = 0.01031
IL-4 3.0 4.8 5.9 6.2 p = 0.0005886
IL-6 136.0 349.1 986.2 5718.1 p = 0.003728
IL-8/CXCL8 36.5 51.2 52.1 59.8 p = 0.009737
IL-10 7.2 5.4 9.2 5.7 p = 0.01423
IL-16 57.6 45.1 118.1 128.7 p = 0.0002389
CXCL10 350.3 1529.3 345.9 521.2 p = 0.0001969
CXCL11 5.0 8.1 6.7 8.8 p = 0.0757
CCL2 1602.8 1597.1 1832.7 1693.6 p = 0.3683
CCL8 12.4 30.6 16.7 21.7 p = 0.0006981
CCL7 21.8 26.0 32.0 31.8 p = 0.01758
CCL13 2.3 2.4 3.5 3.6 p = 0.01689
CCL22 14.0 17.3 22.4 20.2 p = 0.001134
MIF 101278.2 99480.3 127494.3 118058.1 p = 0.1139
MIG/CXCL9 304.1 2254.6 330.3 1208.3 p = 0.0001447
CCL3 3.1 2.7 4.2 3.7 p = 0.005434
CCL15 712.1 600.2 1502.8 1806.4 p = 0.0007773
CCL20 10.9 14.9 20.3 35.1 p = 0.002397
CCL19 38.1 62.8 75.7 122.2 p = 0.0001397
CCL23 17.4 19.9 32.3 38.8 p = 0.0002163
CXCL16 812.5 313.6 945.8 324.0 p = 0.01275
CXCL12 169.6 233.9 280.8 291.1 p = 4.18E-05
CCL17 6.4 19.2 11.2 22.9 p = 0.01808
CCL25 384.9 498.9 526.9 566.7 p = 0.0152
TNF-α 13.3 17.8 17.0 14.3 p = 0.01748
TGF-β1 100.1 215.5 88.9 171.9 p = 0.8986
TGF-β2 1243.6 823.9 1107.2 1078.3 p = 0.08566
TGF-β3 12.3 26.4 12.1 20.9 p = 0.781
https://doi.org/10.1371/journal.pone.0214674.t005
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Table 6. Mean concentrations (pg/ml) and standard deviations (SD) of cytokines in the vitreous of eyes with primary retinal detachment with PVR grade C1, and
in eyes with PVR grade C2 or higher.
Cytokine PVR C1 PVR C2 or higher Mann-Whitney U test
Mean (pg/ml) SD Mean (pg/ml) SD
CCL21 2617.5 3303.7 3268.7 6271.7 p = 0.8537
CXCL13 2.2 2.2 3.6 6.9 p = 0.6189
CCL27 11.0 21.0 29.4 86.2 p = 0.05675
CXCL5 211.5 196.1 174.5 187.2 p = 0.2931
CCL11 20.1 20.0 18.0 19.9 p = 0.665
CCL24 24.3 16.1 31.6 38.8 p = 0.797
CCL26 15.5 19.3 14.4 16.8 p = 0.9795
CX3CL1 95.3 93.8 93.3 91.4 p = 0.9897
CXCL6 3.7 5.7 5.7 7.4 p = 0.1623
GM-CSF 51.1 20.6 51.7 19.5 p = 0.8977
CXCL1 84.9 63.9 81.1 60.2 p = 0.625
CXCL2 52.9 119.0 57.3 96.8 p = 0.6923
CCL1 60.2 79.5 56.0 85.9 p = 0.6037
IFN-γ 12.6 15.2 15.4 17.0 p = 0.5475
IL-1β 1.8 1.8 2.5 3.7 p = 0.589
IL-2 1.8 1.3 1.9 1.5 p = 0.8705
IL-4 5.1 6.2 5.9 6.2 p = 0.5622
IL-6 572.6 1834.9 986.2 5718.1 p = 0.1674
IL-8/CXCL8 43.5 43.5 52.1 59.8 p = 0.7543
IL-10 9.4 4.6 9.2 5.7 p = 0.6099
IL-16 73.6 45.4 118.1 128.7 p = 0.181
CXCL10 387.8 803.8 345.9 521.2 p = 0.1597
CXCL11 7.1 8.6 6.7 8.8 p = 0.7028
CCL2 1951.5 1681.5 1832.7 1693.6 p = 0.3725
CCL8 14.9 23.1 16.7 21.7 p = 0.3611
CCL7 34.0 39.3 32.0 31.8 p = 0.8067
CCL13 3.6 3.8 3.5 3.6 p = 0.5598
CCL22 18.2 21.1 22.4 20.2 p = 0.153
MIF 124323.2 117135.7 127494.3 118058.1 p = 0.7543
MIG/CXCL9 222.7 895.7 330.3 1208.3 p = 0.2169
CCL3 4.5 4.0 4.2 3.7 p = 0.8807
CCL15 1166.5 1704.2 1502.8 1806.4 p = 0.081
CCL20 15.2 17.0 20.3 35.1 p = 0.6099
CCL19 55.8 55.5 75.7 122.2 p = 0.7739
CCL23 22.9 27.8 32.3 38.8 p = 0.1042
CXCL16 994.4 339.3 945.8 324.0 p = 0.6464
CXCL12 211.9 156.9 280.8 291.1 p = 0.474
CCL17 10.4 18.5 11.2 22.9 p = 0.9853
CCL25 571.1 684.8 526.9 566.7 p = 0.9044
TNF-α 18.6 16.2 17.0 14.3 p = 0.6099
TGF-β1 41.8 134.9 88.9 171.9 p = 0.04595
TGF-β2 899.5 677.8 1107.2 1078.3 p = 0.5229
TGF-β3 6.2 16.1 12.1 20.9 p = 0.05585
https://doi.org/10.1371/journal.pone.0214674.t006
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Comparison of cytokine profiles in eyes with pRD without relevant PVR (group 1) and
with PVR requiring a gas (group 2) or silicone oil tamponade (group 3)
We found no significant differences in the VF chemo- or cytokine levels between Groups 1
and 2 (Table 1).
In Group 3, however, the concentrations of 13 chemo-and cytokines (CCL27, CCL26,
CXCL6, IL-4, IL-16, CXCL10, CCL8, CCL22, MIG/CXCL9, CCL15, CCL19, CCL23,
CXCL12) were elevated compared to Group 1 (Table 2). We observed PVR grade of C2 or
higher (C2 to D) in 86.4% of patients from Group 3.Comparison of cytokine profiles in eyes
requiring gas (group 2) or silicone oil tamponade (group 3)A comparison between Groups
2 and 3 yielded only one cytokine, CCL23, with significantly elevated VF levels in group 3
(Table 3).
Comparing cytokine profiles from eyes with pRD and PVR grade A or B to
eyes with PVR grade C1
Patients with pRD with PVR grade B or less displayed one cytokine (CCL19) with elevated lev-
els in comparison to patients with PVR C1, indicating an early change towards more severe
PVR. When compared to patients with more severe PVR (grades C2 to D) the latter showed 12
cytokines with significantly higher VF levels: CCL27, CXCL6, IL4, IL16, CXCL10, CCL8,
CCL22, MIG/CXCL9, CCL15, CCL19, CCL 23 and CXCL12 (Tables 4–6).
Interestingly, comparing the vitreous levels of eyes with PVR C1 and PVR C2-D, no signifi-
cant difference in chemo- and cytokine expression was found (Tables 4–6, Fig 3).
Fig 2. Cytokine levels in the vitreous fluid. Comparing cytokine levels in the vitreous (VF) of eyes of patients with primary
retinal detachment without PVR (pRD; n = 81) with moderate PVR (n = 49), with advanced PVR (n = 44), and eyes with
macular holes.
https://doi.org/10.1371/journal.pone.0214674.g002
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Discussion
The comparison of cytokine profiles in different stages of proliferative vitreoretinopathy
(PVR) in primary retinal detachment (pRD) identified the chemokine (C-C motif) ligand 19
(CCL19) as specifically upregulated in early PVR (C1). In more advanced stages of PVR
(C2-D), 11 additional cytokines (CCL27, CXCL6, IL4, IL16, CXCL10, CCL8, CCL22, MIG/
CXCL9, CCL15, CCL 23 and CXCL12) exhibited higher levels in the vitreous fluid compared
to vitreous from eyes with pRD, but without PVR. When we compared the cytokine profiles in
the pRD group with the most instable retinal situation that received silicone oil (group 3) to
that of the group that received gas filling (group 2), CCL23 was the only cytokine elevated in
the VF. Since 86.4% of group 3 showed severe PVR (C2-D) this cytokine might qualify as a
marker for advanced PVR. This would be supported by the fact that CCL23 is induced by IL-4
and has chemotactic characteristics [25].
We found CCL19 to be the only cytokine upregulated in RD and PVR C1 compared to
pRD with PVR grade B or less. CCl19 specifically binds to the chemokine receptor CCR7
which stimulates dendritic cell maturation [26]. Together with CCL21, CCL19 specifically
binds to CCR7 and is constitutively expressed to control cell movement during homeostasis.
CCR7 and CCL19 are also known to play a role in tissue repair and wound healing [27,28].
Samples of vitreous fluid from eyes with idiopathic epiretinal membranes and/or idiopathic
macular holes have served in many studies as controls for cytokine analyses in various ocular
pathologies [7,29,30]. Due to fibroblast activity in epiretinal membranes and an elevated
inflammatory cytokine profile in the vitreous, we decided to use only patients with macular
hole pathology without concomitant epiretinal membranes as a control group [31,32].
Fig 3. Cytokine levels in the vitreous fluid regarding different PVR grades Cytokine levels in the vitreous (VF) of eyes with
primary retinal detachment without PVR or PVR grades A or B (pRD0-B; n = 81) with PVR grade C1 (pRDC1; n = 27) and
grades C2-D (pRDC2-D; n = 65).
https://doi.org/10.1371/journal.pone.0214674.g003
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When compared to macular holes, the concentrations of almost all tested chemo- and cyto-
kines were elevated in the vitreous of all pRD groups, irrespective of the presence or severity of
PVR. This suggest that comparisons using only a single or very few cytokines may be mislead-
ing. TGF-beta 1- and 2 were the sole cytokines that were not significantly increased. Such
unspecific upregulation of many cytokines may result from a damage to the retinovascular bar-
rier following retinal detachment. Therefore, the cytokine milieu changes may represent a
timely response to the tissue trauma which cannot be attributed to one single biological pro-
cess [16,33,34,35]. The significant upregulation of pro-fibrotic and pro-inflammatory cyto-
kines in eyes with RD compared to MH found in our study is in good agreement with previous
studies that have found similar upregulations compared to eyes with either macular hole, epir-
etinal membrane or retinal vein occlusion, notably for cytokines as IL-6 and IL-8 [1,16,19,20,
36,37], MCP1, MIP-1beta and IP10 [36,38], and in RD with PVR for IL-6, IL-8, IL-10, TNF,
INF-gamma, CCL2, CCL3, CCL4, CCL5, CCL11, CCL17, CCL18, CCL19, CXCL9, CXCL19,
G-CSF and FGF [2,12,39].
Our intention is a better understanding of the impact of local cytokine environmental
changes in the progression of PVR. With the upregulation of 12 out of 43 chemo- and cyto-
kines our findings do not indicate a very targeted or specific local response. This unspecific
change in the intraocular environment during the progression from pRD to severe PVR,
namely PVR grades C2-D may well explain why many therapeutic attempts to date remained
unsuccessful [40,41].
Having identified CCL19 as a possible marker for the early detection of PVR, plus the sub-
sequent upregulation of 11 additional chemo- and cytokines as PVR severity increases, seems
to contradict the commonly held notion of this process being primarily unspecific. This raises
the hope that we may at some point be able to specifically target the tissue response that results
late in the progression of PVR. Currently, it is conceivable that CCL19 could serve as a diag-
nostic marker for the risk of PVR progression.
The main strength of this study is its well-designed selection process with sufficiently large
numbers in each group. While the data is consistent, precise, and reliable, the storage condi-
tions must be regarded as a weak point of this study. Samples were not immediately frozen due
to the fact that our operation room is not close to the lab. This may principally allow a partial
degradation of distinct peptides, chemo- and cytokines, so that we cannot exclude a minor dif-
ference in the absolute cytokine concentrations between sampling and storing. Nevertheless,
this process was the same for all samples from all groups, and therefore cannot explain any of
the inter-group differences we observed. Moreover, the cytokine concentrations in the aque-
ous humour and vitreous fluid reported here and in our previous studies [31,42,43] are well in
line with the concentrations in the ocular fluids of published data from independent groups
[44,45]. One further limitation of this study is the difference in age and gender between the
groups. Both are known to play a role in the immune response [46,47,48,49,50,51]. Though
their impact is unlikely to account for the differences found here, we have to assume that dif-
ferences in age and gender might have added to the results.
In conclusion, we could identify substantial (but not targeted) changes in the cytokine pro-
files in pRD. This lends further support to the importance of unspecific cell activation pro-
cesses over the course of the disease. However, the cellular source responsible for inducing the
increased cytokine concentrations remains to be identified.
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